CLEVELAND — A community in mourning gathered together for a vigil Friday in remembrance of the lives of the two young girls who were found dead inside suitcases in Cleveland's Collinwood neighborhood ...
Novo Nordisk (NVO) is planning to sell its obesity drugs on the telehealth platform run by Hims & Hers Health (HIMS) as part of a partnership between the two firms, Bloomberg reported, citing a person ...
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little March 6 (Reuters) - Wegovy maker Novo ...
Novo Nordisk has reached a deal to sell its weight-loss drugs on Hims & Hers’ online platform, one month after threatening legal action when the telehealth company announced plans to market a $49 copy ...
CLEVELAND (AP) — A Cleveland judge set bail at $2 million Friday for a woman accused of killing her two young daughters and burying them in suitcases in shallow graves. Aliyah Henderson, 28, faces two ...
Novo Nordisk shares sank after the Danish drugmaker suffered a setback in its battle with Eli Lilly to dominate the market for weight-loss drugs.
Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027. The move aims to make the treatments more ...
The weight-loss drugs that kicked off America's GLP-1 craze are about to get a lot less expensive, though only certain customers will notice the savings. Novo Nordisk said it will slash list prices of ...
Novo hoped its next obesity drug would close the gap. Instead, it may have widened Eli Lilly’s lead.
LONDON, Feb 24 (Reuters) - With U.S. arch rival Eli Lilly (LLY.N), opens new tab streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk (NOVOb.CO), opens new tab needed ...
Novo Nordisk NOVO.B6.03%increase; green up pointing triangle shares fell 16% after the Danish drugmaker said its next-generation obesity treatment failed to outperform Eli Lilly’s Zepbound in a ...
Novo Nordisk’s experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly’s Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results